A progressive, fatal dystonia‐Parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy
- 22 June 2007
- journal article
- case report
- Published by Wiley in Movement Disorders
- Vol. 22 (11) , 1664-1666
Abstract
X‐linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by a mutation in the Bruton agammaglobulinemia tyrosine kinase gene that results in severe B‐cell deficiency. So far, neurological complications of XLA have been primarily related to acute and/or chronic central nervous system enteroviral infections. In the last few years a progressive neurodegenerative syndrome of unknown etiology has been described in XLA patients. We describe and present a video of an XLA patient who developed a fatal dementing, dystonia‐Parkinsonism syndrome 14 years into his immune disorder. Physician awareness of this rare syndrome may lead to its better characterization and management. © 2007 Movement Disorder SocietyKeywords
This publication has 13 references indexed in Scilit:
- X-Linked AgammaglobulinemiaMedicine, 2006
- Intravenous Immunoglobulin: New Indications and Mechanisms of ActionClinical Reviews in Allergy & Immunology, 2005
- Progressive Neurodegeneration in Patients with Primary Immunodeficiency Disease on IVIG TreatmentClinical Immunology, 2002
- A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndromeNature Genetics, 2001
- The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding proteinNature Genetics, 1997
- A novel X–linked gene, DDP, shows mutations in families with deafness (DFN–1), dystonia, mental deficiency and blindnessNature Genetics, 1996
- Encephalomyelitis in primary hypogammaglobulinaemiaBrain, 1996
- The Primary ImmunodeficienciesNew England Journal of Medicine, 1995
- The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinasesNature, 1993
- Chronic Enteroviral Meningoencephalitis in Agammaglobulinemic PatientsClinical Infectious Diseases, 1987